ArticleCurrent medicinal chemistry2026
Comprehensive Pan-cancer analysis of Pyroglutamylated RFamide Peptide Receptor: Its Potential Biological Functions and Associations with Prognosis and Immunity.
Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe receptor for pyroglutamylated RF amide peptide (QRFPR) is a G protein-coupled receptor that plays a role in various physiological and pathological processes. However, a gap remains in our understanding of QRFPR's pan-cancer properties.
methodsThis study performs an extensive pan-cancer analysis of QRFPR utilizing large-scale genomic datasets, including The Cancer Genome Atlas (TCGA). We evaluated QRFPR expression levels in multiple malignancies and examined their correlations with clinical outcomes. Additionally, we investigated associations between QRFPR expression and immune cell infiltration using bioinformatics tools.
resultsOur results reveal significant alterations in QRFPR expression across several cancer types, particularly breast, colorectal, and prostate cancers. Elevated levels of QRFPR are linked to poor prognosis in certain malignancies, such as uterine corpus endometrial carcinoma (UCEC) and mesothelioma (MESO), and correlate with increased infiltration of immune cells, especially T cells and macrophages. Pathway enrichment analyses suggest that QRFPR may impact critical signaling pathways associated with cell growth, apoptosis, and immune regulation. DISCUSSION: The observed variations in QRFPR expression across cancer types suggest its diverse roles in tumor biology. Its association with unfavorable clinical outcomes in specific cancers, as well as its link to immune cell infiltration, highlights its multifaceted impact on tumor progression and microenvironment modulation.
conclusionOur findings underscore the potential of QRFPR as a prognostic biomarker and therapeutic target in cancer biology. Further investigations into its functional mechanisms could pave the way for precision medicine approaches in oncology.
Indexed as
Identifiers
41029021What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.